CC BY 4.0 · Rev Bras Ginecol Obstet 2022; 44(09): 891-898
DOI: 10.1055/s-0042-1755459
Review Article

The Effect of Neuromodulatory Drugs on the Intensity of Chronic Pelvic Pain in Women: A Systematic Review

Efeito de neuromoduladores na intensidade da dor pélvica crônica em mulheres: Revisão sistemática
1   Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
,
1   Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
,
1   Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brazil
› Author Affiliations

Abstract

Objective: To evaluate the effect of neuromodulatory drugs on the intensity of chronic pelvic pain (CPP) in women.

Data sources: Searches were carried out in the PubMed, Cochrane Central, Embase, Lilacs, OpenGrey, and Clinical Trials databases.

Selection of studies: The searches were carried out by two of the authors, not delimiting publication date or original language. The following descriptors were used: chronic pelvic pain in women OR endometriosis, associated with MESH/ENTREE/DeCS: gabapentinoids, gabapentin, amitriptyline, antidepressant, pregabalin, anticonvulsant, sertraline, duloxetine, nortriptyline, citalopram, imipramine, venlafaxine, neuromodulation drugs, acyclic pelvic pain, serotonin, noradrenaline reuptake inhibitors, and tricyclic antidepressants, with the Boolean operator OR. Case reports and systematic reviews were excluded.

Data collection: The following data were extracted: author, year of publication, setting, type of study, sample size, intervention details, follow-up time, and results.

Data synthesis: A total of 218 articles were found, with 79 being excluded because they were repeated, leaving 139 articles for analysis: 90 were excluded in the analysis of the titles, 37 after reading the abstract, and 4 after reading the articles in full, and 1 could not be found, therefore, leaving 7 articles that were included in the review.

Conclusion: Most of the studies analyzed have shown pain improvement with the help of neuromodulators for chronic pain. However, no improvement was found in the study with the highest statistical power. There is still not enough evidence that neuromodulatory drugs reduce the intensity of pain in women with CPP.

Resumo

Objetivo: Avaliar o efeito de drogas neuromoduladoras na intensidade da dor pélvica crônica em mulheres.

Fontes de dados: As buscas foram realizadas nas bases de dados PubMed, Cochrane Central, Embase, Lilacs, OpenGrey e Clinical Trials.

Seleção dos estudos: As buscas foram realizadas por dois dos autores, não delimitando data de publicação ou idioma de publicação. Foram usados os seguintes descritores: chronic pelvic pain in women OR endometriosis, associated with MESH/ENTREE/DeCS: gabapentinoids, gabapentin, amitriptyline, antidepressant, pregabalin, anticonvulsant, sertraline, duloxetine , nortriptyline, citalopram, imipramine, venlafaxine, neuromodulation drugs, acyclic pelvic pain, serotonin, noradrenaline reuptake inhibitors e tricyclic antidepressants, com o operador booleano OR. Relatos de caso e revisões sistemáticas foram excluídos.

Coleta de dados: Foram extraídos os seguintes dados: autor, ano de publicação, local de origem, tipo de estudo, tamanho da amostra, detalhes da intervenção, tempo de seguimento e resultados.

Síntese dos dados: Foram encontrados 218 artigos, sendo 79 deles excluídos por serem repetidos, restando 139 artigos para análise, dos quais 90 foram excluídos na análise dos títulos, 37 após a leitura do resumo e 4 após a leitura dos artigos na íntegra, e 1 não foi encontrado, restando, então, 7 artigos que foram incluídos na revisão.

Conclusão: A maioria dos estudos analisados mostrou melhora da dor crônica com auxílio de neuromoduladores. No entanto, nenhuma melhora foi encontrada no artigo com maior poder estatístico. Ainda não há evidências suficientes de que drogas neuromoduladoras reduzam a intensidade da dor pélvica crônica em mulheres.



Publication History

Received: 13 January 2022

Accepted: 03 June 2022

Article published online:
31 August 2022

© 2022. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 
  • References

  • 1 Carey ET, As-Sanie S. New developments in the pharmacotherapy of neuropathic chronic pelvic pain. Future Sci OA 2016; 2 (04) FSO148
  • 2 Martínez B, Canser E, Gredilla E, Alonso E, Gilsanz F. Management of patients with chronic pelvic pain associated with endometriosis refractory to conventional treatment. Pain Pract 2013; 13 (01) 53-58
  • 3 Kremer M, Salvat E, Muller A, Yalcin I, Barrot M. Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights. Neuroscience 2016; 338: 183-206
  • 4 Paiva S, Carneiro MM. Complementary and alternative medicine in the treatment of chronic pelvic pain in women: what is the evidence?. ISRN Pain 2013; 2013: 469575
  • 5 Giamberardino MA, Tana C, Costantini R. Pain thresholds in women with chronic pelvic pain. Curr Opin Obstet Gynecol 2014; 26 (04) 253-259
  • 6 Sator-Katzenschlager SM, Scharbert G, Kress HG, Frickey N, Ellend A, Gleiss A. et al. Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study. Wien Klin Wochenschr 2005; 117 (21-22): 761-768
  • 7 Farghaly HSM, Elbadr MM, Ahmed MA, Abdelhaffez AS. Effect of single and repeated administration of amitriptyline on neuropathic pain model in rats: Focus on glutamatergic and upstream nitrergic systems. Life Sci 2019; 233: 116752
  • 8 Horne AW, Vincent K, Hewitt CA, Middleton LJ, Koscielniak M, Szubert W. et al; GaPP2 collaborative. Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2020; 396 (10255): 909-917
  • 9 Walker EA, Sullivan MD, Stenchever MA. Use of antidepressants in the management of women with chronic pelvic pain. Obstet Gynecol Clin North Am 1993; 20 (04) 743-751
  • 10 Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372 (71) n71
  • 11 Rai AS, Khan JS, Dhaliwal J, Busse JW, Choi S, Devereaux PJ. et al. Preoperative pregabalin or gabapentin for acute and chronic postoperative pain among patients undergoing breast cancer surgery: A systematic review and meta-analysis of randomized controlled trials. J Plast Reconstr Aesthet Surg 2017; 70 (10) 1317-1328
  • 12 Agarwal MM, Elsi Sy M. Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin?. Neurourol Urodyn 2017; 36 (08) 2028-2033
  • 13 Engel Jr CC, Walker EA, Engel AL, Bullis J, Armstrong A. A randomized, double-blind crossover trial of sertraline in women with chronic pelvic pain. J Psychosom Res 1998; 44 (02) 203-207
  • 14 Seretny M, Murray SR, Whitaker L, Murnane J, Whalley H, Pernet C. et al. The use of brain functional magnetic resonance imaging to determine the mechanism of action of gabapentin in managing chronic pelvic pain in women: a pilot study. BMJ Open 2019; 9 (06) e026152
  • 15 Walker EA, Roy-Byrne PP, Katon WJ, Jemelka R. An open trial of nortriptyline in women with chronic pelvic pain. Int J Psychiatry Med 1991; 21 (03) 245-252
  • 16 Lewis SC, Bhattacharya S, Wu O, Vincent K, Jack SA, Critchley HO. et al. Gabapentin for the management of chronic pelvic pain in women (GaPP1): a pilot randomised controlled trial. PLoS One 2016; 11 (04) e0153037
  • 17 AbdelHafeez MA, Reda A, Elnaggar A, El-Zeneiny H, Mokhles JM. Gabapentin for the management of chronic pelvic pain in women. Arch Gynecol Obstet 2019; 300 (05) 1271-1277
  • 18 Walitt B, Urrútia G, Nishishinya MB, Cantrell SE, Häuser W. Selective serotonin reuptake inhibitors for fibromyalgia syndrome. Cochrane Database Syst Rev 2015; 2015 (06) CD011735
  • 19 Patetsos E, Horjales-Araujo E. Treating chronic pain with SSRIs: what do we know?. Pain Res Manag 2016; 2016: 2020915
  • 20 Lee RA, West RM, Wilson JD. The response to sertraline in men with chronic pelvic pain syndrome. Sex Transm Infect 2005; 81 (02) 147-149
  • 21 Urits I, Peck J, Orhurhu MS, Wolf J, Patel R, Orhurhu V. et al. Off-label antidepressant use for treatment and management of chronic pain: evolving understanding and comprehensive review. Curr Pain Headache Rep 2019; 23 (09) 66
  • 22 Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci 2017; 18 (11) 2483
  • 23 Khouzam HR. Psychopharmacology of chronic pain: a focus on antidepressants and atypical antipsychotics. Postgrad Med 2016; 128 (03) 323-330
  • 24 Vincent K, Baranowski A, Bhattacharya S, Birch J, Cheong Y, Cregg R. et al. GaPP2, a multicentre randomised controlled trial of the efficacy of gabapentin for the management of chronic pelvic pain in women: study protocol. BMJ Open 2018; 8 (01) e014924
  • 25 Mimenza Alvarado A, Aguilar Navarro S. Clinical trial assessing the efficacy of gabapentin plus b complex (B1/B12) versus pregabalin for treating painful diabetic neuropathy. J Diabetes Res 2016; 2016: 4078695
  • 26 Senderovich H, Jeyapragasan G. Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true?. Curr Med Res Opin 2018; 34 (04) 677-682